These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30174151)

  • 1. Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.
    Hymel D; Grant RA; Tsuji K; Yaffe MB; Burke TR
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3202-3205. PubMed ID: 30174151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.
    Qian WJ; Park JE; Lim D; Lai CC; Kelley JA; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
    Biopolymers; 2014 Nov; 102(6):444-55. PubMed ID: 25283071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
    Chen Y; Li Z; Liu Y; Lin T; Sun H; Yang D; Jiang C
    Bioorg Chem; 2018 Dec; 81():278-288. PubMed ID: 30170276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Sun H; Xu L; Jiang C
    Bioorg Chem; 2019 Oct; 91():103148. PubMed ID: 31376784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
    Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
    Zhao XZ; Hymel D; Burke TR
    Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer.
    Kim TG; Lee JH; Lee MY; Kim KU; Lee JH; Park CH; Lee BH; Oh KS
    Biol Pharm Bull; 2017; 40(9):1454-1462. PubMed ID: 28867728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles.
    Hymel D; Tsuji K; Grant RA; Chingle RM; Kunciw DL; Yaffe MB; Burke TR
    Org Biomol Chem; 2021 Sep; 19(36):7843-7854. PubMed ID: 34346472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.
    Reindl W; Gräber M; Strebhardt K; Berg T
    Anal Biochem; 2009 Dec; 395(2):189-94. PubMed ID: 19716361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.
    Abdelfatah S; Fleischer E; Klinger A; Wong VKW; Efferth T
    Invest New Drugs; 2020 Feb; 38(1):1-9. PubMed ID: 30877426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
    Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
    Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1.
    Alverez CN; Park JE; Toti KS; Xia Y; Krausz KW; Rai G; Bang JK; Gonzalez FJ; Jacobson KA; Lee KS
    J Med Chem; 2020 Nov; 63(22):14087-14117. PubMed ID: 33175530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
    Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
    Ryu S; Park JE; Ham YJ; Lim DC; Kwiatkowski NP; Kim DH; Bhunia D; Kim ND; Yaffe MB; Son W; Kim N; Choi TI; Swain P; Kim CH; Lee JY; Gray NS; Lee KS; Sim T
    J Med Chem; 2022 Feb; 65(3):1915-1932. PubMed ID: 35029981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.
    Qian WJ; Park JE; Lim D; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
    Chem Biol; 2013 Oct; 20(10):1255-64. PubMed ID: 24120332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
    Yun SM; Moulaei T; Lim D; Bang JK; Park JE; Shenoy SR; Liu F; Kang YH; Liao C; Soung NK; Lee S; Yoon DY; Lim Y; Lee DH; Otaka A; Appella E; McMahon JB; Nicklaus MC; Burke TR; Yaffe MB; Wlodawer A; Lee KS
    Nat Struct Mol Biol; 2009 Aug; 16(8):876-82. PubMed ID: 19597481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.
    Baxter M; Chapagai D; Craig S; Hurtado C; Varghese J; Nurmemmedov E; Wyatt MD; McInnes C
    ChemMedChem; 2020 Jun; 15(12):1058-1066. PubMed ID: 32232973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.